The clonoSEQ® Watch Registry
Recruiting in Palo Alto (17 mi)
+15 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Adaptive Biotechnologies
No Placebo Group
Trial Summary
What is the purpose of this trial?
This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.
Research Team
HS
Heidi Simmons, PhD
Principal Investigator
Adaptive Biotechnologies
Eligibility Criteria
Inclusion Criteria
Patients must be able to provide written informed consent
A decision has been made by the treating provider to use the clonoSEQ Assay as part of routine clinical care
Age ≥ 18 years;
See 5 more
Treatment Details
Interventions
- clonoSEQ Assay (Diagnostic Test)
Participant Groups
4Treatment groups
Experimental Treatment
Group I: NHLExperimental Treatment1 Intervention
patients diagnosed with non-Hodgkin lymphoma
Group II: MMExperimental Treatment1 Intervention
patients diagnosed with multiple myeloma
Group III: CLLExperimental Treatment1 Intervention
patients diagnosed with chronic lymphocytic leukemia
Group IV: ALLExperimental Treatment1 Intervention
patients diagnosed with acute lymphoblastic leukemia
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
University of Colorado - Anschutz Medical CampusAurora, CO
Northwest Medical SpecialistsTacoma, WA
Holy Cross HospitalFort Lauderdale, FL
Washington UniversitySaint Louis, MO
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Adaptive Biotechnologies
Lead Sponsor
Trials
14
Patients Recruited
3,700+